« Back
Home /
Erlotinib

Erlotinib

Item no.	HY-50896-10mM
Manufacturer	MedChem Express
CASRN	183321-74-6
Amount	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 1 g 500 mg 5 g
Category	Oncology Neuroscience Metabolism Diabetes Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer
Type	Inhibitors
Specific against	other
Purity	99.99
Citations	[1]Moyer JD, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997, 57(21), 4838-4848.\|[2]Ali S, et al. Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther, 2008, 7(6), 1708-1719.\|[3]Wada Y, et al. Epidermal growth factor receptor inhibition with erlotinib partially prevents cisplatin-induced nephrotoxicity in rats. PLoS One. 2014 Nov 12;9(11):e111728. ACS Omega. 2025 Oct 29;10(44):52562–52575. Acta Pharmacol Sin. 2021 Jan;42(1):108-114. Adv Ther. 2024 Jul 18. Allergy. 2025 May;80(5):1335-1347. Anal Chim Acta. 2018 Nov 22:1032:138-146. Bioact Mater. 2021 Nov 4;13:312-323. Bioact Mater. 2024 May 11:38:384-398. Biochem Biophys Res Commun. 2022 Dec 25;636(Pt 1):125-131. Biochem Biophys Res Commun. 2024 Sep 19:733:150711. Biochem Pharmacol. 2025 Jul 18:241:117183. Bioengineering (Basel). 2025 Oct 19;12(10):1121. Biol Methods Protoc. 2025 Feb 13;10(1):bpaf012. Biomaterials. 2022 Oct:289:121800. Biomed Chromatogr. 2016 Jul;30(7):1150-4. Biomed Chromatogr. 2024 Nov 7:e6039. Biomed Pharmacother. 2024 Jun:175:116644. Biomed Res Int. 2019 Nov 28;2019:2410845. Bioorg Chem. 2025 Aug 9:164:108864. bioRxiv. 2019 Sep. bioRxiv. 2023 Oct 20:2023.10.19.563158. bioRxiv. 2024 Dec 20:2024.12.19.629301. bioRxiv. 2025 Sep 21. bioRxiv. October 28, 2021. Br J Cancer. 2023 Feb;128(4):678-690. Breast Cancer Res Treat. 2025 Jun;211(2):467-478. Cancer Cell. 2025 Jul 25:S1535-6108(25)00310-1. Cancer Lett. 2025 Apr 10:217715. Cancer Manag Res. 2024 May 28:16:507-525. Cancer Med. 2019 Dec;8(18):7793-7808. Cancer Med. 2024 May;13(10):e7083. Cancer Res Treat. 2023 Jul;55(3):778-803. Cancer Res Treat. 2023 Oct;55(4):1077-1086. Cancer Res. 2024 Feb 1;84(3):479-492. Cancers (Basel). 2022 Jun 5;14(11):2807. Cell Biol Toxicol. 2021 Apr;37(2):313-330. Cell Death Differ. 2024 Sep;31(9):1140-1156. Cell Death Dis. 2022 Dec 27;13(12):1075. Cell Death Dis. 2022 Jan 13;13(1):55. Cell Death Discov. 2025 May 17;11(1):241. Cell Insight. 2022 Jun 16;1(4):100045. Cell Rep Med. 2023 Feb 21;4(2):100911. Cell Rep Med. 2025 Apr 2:102053. Cell Rep. 2024 Mar 27;43(4):114002. Cell Res. 2020 Oct;30(10):833-853. Cell Syst. 2020 Nov 18;11(5):478-494.e9. Commun Biol. 2021 Dec 13;4(1):1391. Complutense University of Madrid. 2025. Dev Cell. 2025 Sep 29:S1534-5807(25)00539-8. Ecotoxicol Environ Saf. 2023 Jan 1:249:114386. Ecotoxicol Environ Saf. 2024 Oct 15:285:117031. EMBO J. 2025 Mar;44(5):1464-1487. Exp Cell Res. 2020 Aug 1;393(1):112054. Exp Cell Res. 2021 Feb 1;399(1):112424. Front Pharmacol. 2018 Jun 21:9:660. Front Pharmacol. 2022 Apr 8;13:879751. Genome Med. 2021 Sep 1;13(1):142. Harvard Medical School LINCS LIBRARY Hum Reprod Open. 2025 May 14;2025(3):hoaf027. Int J Biol Macromol. 2023 Oct 1:250:126147. J Cancer. 2024 Mar 25;15(10):2891-2899. J Cell Mol Med. 2020 Jan;24(2):1969-1979. J Clin Invest. 2020 Mar 2;130(3):1417-1430. J Control Release. 2024 Dec:376:829-841. J Enzyme Inhib Med Chem. 2025 Dec;40(1):2501743. J Exp Clin Cancer Res. 2021 Jan 9;40(1):25. J Exp Clin Cancer Res. 2024 Nov 20;43(1):308. J Invest Dermatol. 2019 Jan;139(1):224-234. J Med Food. 2018 Jul;21(7):701-708. J Nutr Biochem. 2023 Sep:119:109399. J Pharm Anal. 2021 Dec;11(6):799-807. Lung Cancer. 2024 Apr 11. Mar Drugs. 2024 Sep 28;22(10):444. Mol Cancer Res. 2019 Nov;17(11):2233-2243. Mol Carcinog. 2022 Jul;61(7):664-676. Mol Cell. 2022 Jul 7;82(13):2443-2457.e7. Mol Cell. 2023 Dec 7;83(23):4334-4351.e7. Mol Divers. 2025 Jun;29(3):2391-2405. Mol Oncol. 2018 Mar;12(3):305-321. Mol Oncol. 2023 Dec;17(12):2618-2636. Mol Pharm. 2021 Jul 5;18(7):2495-2506. Nat Commun. 2023 Apr 24;14(1):2342. Nat Commun. 2023 Mar 28;14(1):1726. Nat Commun. 2019 Apr 18;10(1):1812 Neurobiol Dis. 2020 Aug;142:104961. Oncogene. 2017 May 11;36(19):2643-2654. Oncogene. 2021 Apr;40(14):2596-2609. Oncogene. 2021 Jul;40(30):4884-4893. Oncogene. 2022 May;41(22):3064-3078. Oncogene. 2023 Sep;42(39):2869-2877. Oncol Rep. 2016 Dec;36(6):3588-3596. Oncol Rep. 2021 Mar;45(3):1306-1314. Oncotarget. 2017 Dec 2;8(68):112313-112329. Patent. US20240344020A1 Patent. US20240344020A1. Pharmaceuticals (Basel). 2024 Dec 16;17(12):1696. PLoS One. 2018 Jun 14;13(6):e0199208. PLoS One. 2024 Nov 1;19(11):e0308647. PLoS Pathog. 2024 Aug 5;20(8):e1012437. Proc Natl Acad Sci U S A. 2024 May 21;121(21):e2403685121. Proteomes. 2023 Jun 2;11(2):20. Res Sq. 2025 Jun 24:rs.3.rs-6456987. Research Square Preprint. 2021 May. Research Square Preprint. 2022 Jun. Research Square Preprint. 2024 Nov 26. Saudi Pharm J. 2023 Oct;31(10):101756. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. SSRN. 31 Aug 2021. Stem Cell Res Ther. 2022 Jun 21;13(1):269. Stem Cells. 2022 May 27;40(5):508-522. Thorac Cancer. 2020 Oct;11(10):2858-2866. Virulence. 2022 Dec;13(1):1849-1867. Viruses. 2020 Jun 10;12(6):628. Am J Transl Res. 2020 May 15;12(5):2295-2304. Cell Rep Methods. 2023 Feb 21;3(2):100411. Cell Rep Methods. 2023 Oct 23;3(10):100599. Cell Rep. 2023 May 29;42(6):112570. CNS Neurosci Ther. 2022 Jan;28(1):64-76. Nat Immunol. 2022 Feb;23(2):251-261. SSRN. 2025 Sep 25.
Smiles	C#CC1=CC=CC(NC2=NC=NC3=C2C=C(C(OCCOC)=C3)OCCOC)=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CP-358774,NSC 718781,OSI-774
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - Targets	Autophagy; EGFR
Manufacturer - HS Code	H302, H315, H319, H335
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	393.44
Product Description	Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer[1]. Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Manufacturer - Research Area	Cancer
Solubility	DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Clinical information	Launched
Isoform	EGFR/ErbB1/HER1
UNSPSC Code	12352005
Precautionary	H302, H315, H319, H335

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.